ArcovaarcovaResources
Sign inStart for free
Resources/Using a PDUFA date to time outreach
Resources

How to use a PDUFA date to time outreach

A PDUFA date is a target action date tied to FDA review-performance goals, not a mandatory approval cutoff. When a company discloses one, it can still be useful sales timing: work the run-up while the company prepares for possible launch, plan for approval and non-approval outcomes, and let the public FDA action set the message that follows.

8 min readUpdated Jul 20, 2026

Most sales triggers in life science arrive as news: a raise closes, a hire starts, a trial reads out, and the clock starts the moment you hear about it. A PDUFA date is different. When it is announced months ahead, it is one of the few buying-timing events you can plan around on a calendar instead of reacting to. Few sellers actually do, which is exactly why it is worth doing well.

  1. Find the date

    A PDUFA target date usually becomes public when the company announces that the FDA has accepted its application for review. That acceptance press release, often phrased along the lines of "the FDA has accepted the filing and assigned a PDUFA target action date of...", is the primary source, and the date is typically repeated in investor presentations from then on. The underlying clock depends on the application cohort. Under PDUFA VII, the standard and priority goals for NME NDAs and original BLAs are ten and six months, respectively, from the 60-day filing date; for non-NME original NDAs, the same standard and priority clocks run from receipt. Do not back-calculate when the company has already disclosed the actual target action date. For accounts you care about, the public date can provide enough lead time to plan rather than react.

  2. Confirm the account fits first

    A PDUFA date is dramatic, and drama is exactly how sellers end up chasing accounts that were never going to buy. The milestone changes when to reach out, not whether the account is worth it. Run the same company-fit and buyer-fit checks you would apply anywhere else, see how to score account fit, and only build a milestone plan for accounts that clear them.

  3. Work the run-up window

    The months before a PDUFA date are among the busiest in a biotech's life, because the company has to prepare as if approval is coming without knowing that it is. Manufacturing and quality teams get the product and the facility ready for commercial scale and possible inspection. Commercial, market access, and medical affairs teams are hired and briefed. Regulatory affairs is deep in the review itself. All of that is work a vendor can help with, and all of it is happening before the target action date.

    Outreach in this window should name the milestone plainly and speak to the preparation: the message is "you have a target action date coming and a mountain of readiness work between now and then," not "congratulations in advance." Hiring activity in commercial, quality, or regulatory roles during this period is a useful confirming clue that the build-up is really underway.

  4. Plan for both outcomes

    A target action date does not guarantee action on that day. Still, a prepared seller can draft separate next messages for two public FDA actions before either one arrives:

    Approval

    The company shifts to launch mode

    Commercial scale-up, launch execution, and continued hiring. Concrete needs often continue across manufacturing, quality, commercial, and medical affairs.

    Complete response letter

    The company regroups

    A formal "not in its current form" from the FDA. Near-term buying usually slows while the company works out its response. Warm, not dead.

    The one hard rule: no outcome-specific message goes out before the outcome is public. A premature congratulations note before an action that turns into a complete response letter is the kind of email that gets forwarded around a leadership team for the wrong reasons.

  5. Let the result set the next message

    After an approval, do not treat the moment as a one-day event. The launch build-out that follows plays out over months, so a relevant message a few weeks after approval is still well inside the window, and often lands better than one fighting through the congratulations flood on day one. After a complete response letter, the right move is patience: keep the account on the watch list and re-engage when something positive becomes public, such as an announced resubmission or a new milestone on another program. See timing outreach with readiness signals for how fast different events fade, and regulatory and FDA signals for the full family of regulatory events around this one.

Checklist

  • PDUFA dates collected for named accounts from company announcements and investor materials.
  • Accounts with an upcoming date re-checked against company and buyer fit before any milestone plan.
  • Run-up outreach sent months out, speaking to launch-readiness work without presuming the outcome.
  • Follow-up messages drafted for both approval and a complete response letter before the target action date.
  • Post-action plan in motion: work the launch window after an approval, or watch quietly for the next positive change after a CRL.
Where Arcova fits: the calendar half of this play is yours; the outcome half is where watching pays off. Arcova monitors public FDA and regulatory milestones, approvals, priority review, designations, and complete response letters, along with the funding and hiring activity that builds up around a regulatory milestone, across your fit-qualified accounts, and flags the account when a real event lands. When a public FDA action arrives, you hear about the outcome from your account list, not from a competitor's congratulations post.
Free preview

See it on your own company

Enter your company domain and Arcova maps your market and target buyers free. No login, about a minute.

Try it free →
Free preview

See it on your own company

Enter your company domain and Arcova maps your market and target buyers free. No login, about a minute.

Try it free →

Frequently asked questions

What exactly is a PDUFA date?

It is the target action date associated with FDA review-performance goals under the Prescription Drug User Fee Act. Under PDUFA VII, FDA aims to review and act on 90% of standard and priority NME NDAs and original BLAs within ten and six months, respectively, of the 60-day filing date. For standard and priority non-NME original NDAs, those ten- and six-month clocks run from receipt. It is a planning milestone, not a promise of approval or a guaranteed FDA action on that day.

Where do I find PDUFA dates for my target accounts?

The most reliable public source is usually the company itself. Many companies name the PDUFA target action date in the FDA filing-acceptance announcement and repeat it in investor presentations. Industry press and investor-focused FDA calendars aggregate upcoming dates as well, but for outreach planning you should verify the date against company communications.

Do PDUFA dates ever move?

Yes. A major amendment submitted during review can extend the goal date, commonly by three months for current PDUFA review cycles, and FDA guidance limits that extension logic to specific circumstances such as reviewing new information that could address outstanding deficiencies. A plan built on a PDUFA date should allow for updates and should treat the date as a timing anchor rather than an exact appointment.

Is it safe to write outreach that assumes the drug will be approved?

No. FDA may issue a complete response letter, its formal notice that it will not approve the application in its current form, and a message that presumed approval reads badly on every desk in that building afterward. The run-up message should speak to the preparation work that is happening either way; the outcome-specific message waits for a public FDA action.

Who inside the company is actually affected by an approaching PDUFA date?

More functions than you might expect. Regulatory affairs is managing the review itself; manufacturing and quality are preparing to produce at commercial scale, including readiness for FDA facility inspection; commercial and medical affairs teams are being hired and briefed for a possible launch; and finance is planning around both outcomes. Which of those threads is your entry point depends on what you sell, but the date pulls on all of them at once.

Does the same approach work for other public FDA milestones?

Largely, yes. An advisory committee meeting, a public session where outside experts review the evidence and vote on a recommendation before some FDA decisions, is also scheduled and announced in advance, and the same before-and-after logic applies. Designations like priority review, fast track, and breakthrough therapy are announced when granted rather than scheduled, so they act as regular readiness signals rather than calendar events, but they tell you a program is moving faster toward the moments this article is about.

Related reading

Guides

Regulatory and FDA signals

FDA approvals, Fast Track, Breakthrough Therapy, Priority Review, and Orphan Drug designations are dated public evidence of where a life science program stands with the regulator and where it is heading. Here is how to read each one and reach the account before your competitors do.

Guides

Timing outreach with readiness

When to reach out to a life science account, not just who to target: the readiness dimensions behind a buying signal, how quickly they should be acted on, and why they decay at different rates.

How-to

How to time outreach

The operational playbook for timing outreach off buying signals: how often to check for new signals, how fast to respond by signal type, recency windows, and what to say versus leave out.

See it on your own market

Score the accounts you already have against your ICP.

Bring in the data you already work with, from your CRM or the providers you already use, and Arcova scores it against your ICP, watches for the life science signals that matter, and tells you who is ready for outreach and why.

Start for free
HomeResourcesArcova SignalsCompareHelp centerPrivacyTermsContact
© 2026 Arcova. All rights reserved.